Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Brunelle returns to Olympics with new outlook

February 8, 2026

Digital car keys are getting more sophisticated

February 8, 2026

Mutuum Finance (MUTM) Crosses $20.4M Funding Milestone After Recent Whale Activity

February 8, 2026

Canada coach looking for cross-country ski medals

February 8, 2026

Coach says Kingsbury races like a Formula One car

February 8, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Texas lawsuit against companies behind Tylenol asserts unproven claims of autism risk
Health

Texas lawsuit against companies behind Tylenol asserts unproven claims of autism risk

By News RoomOctober 28, 20253 Mins Read
Texas lawsuit against companies behind Tylenol asserts unproven claims of autism risk
Share
Facebook Twitter LinkedIn Pinterest Email
Texas lawsuit against companies behind Tylenol asserts unproven claims of autism risk

Texas Attorney General Ken Paxton on Tuesday accused the companies behind Tylenol of deceptively marketing the pain reliever to pregnant mothers in a lawsuit that asserted unproven claims that early exposure to acetaminophen increased risk of autism and other disorders.

Paxton, an ally of President Donald Trump and a Republican candidate for U.S. Senate, announced the suit against Johnson & Johnson and Kenvue weeks after Trump and Health Secretary Robert F. Kennedy Jr. asserted an unproven link between the pain reliever and autism while announcing a wide-ranging effort to study the causes of the complex brain disorder.

The suit alleges that the companies violated Texas consumer protection laws by hiding the danger that acetaminophen, the active ingredient in Tylenol, posed to fetuses and young children and “deceptively marketed Tylenol as the only safe painkiller for pregnant women.”

It also alleges that Johnson & Johnson fraudulently transferred liabilities arising from Tylenol to Kenvue to shield assets against lawsuits.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.

In 2021, New Brunswick, New Jersey-based J&J, announced that it would turn its consumer health business, which makes Tylenol and other products, into a separate company now known as Kenvue. It referenced that divestment in a statement Tuesday, saying “all rights and liabilities associated with the sale of its over-the-counter products, including Tylenol (acetaminophen), are owned by Kenvue.”


“Big Pharma betrayed America by profiting off of pain and pushing pills regardless of the risks. These corporations lied for decades, knowingly endangering millions to line their pockets,” Paxton said in a statement. “Additionally, seeing that the day of reckoning was coming, Johnson & Johnson attempted to escape responsibility by illegally offloading their liability onto a different company.”

Acetaminophen has long been one of the most popular pain relievers and fever reducers in the U.S., used by upward of 100 million Americans annually. Some studies have raised the possibility that taking Tylenol in pregnancy might be associated with a risk of autism — but many others haven’t found a connection.

Kenvue stressed in a statement Tuesday that acetaminophen is the safest pain reliever option for pregnant women, noting that high fevers and pain are recognized as potential risks to pregnancies if left untreated. The Summit, New Jersey-based company said it would defend itself against the claims and expressed concern about the “perpetuation of misinformation” about acetaminophen’s safety and the potential impact on the health of women and children.

“We stand firmly with the global medical community that acknowledges the safety of acetaminophen and believe we will continue to be successful in litigation as these claims lack legal merit and scientific support,” Kenvue said.

Kenvue has said it faces litigation in federal court over the autism claims, noting earlier this year in an annual filing that many of those claims have been dismissed but are being appealed.

&copy 2025 The Canadian Press

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

High blood pressure drug recalled over low blood pressure pill mix-up

Lifestyle factors are behind 4 in 10 new cancers, WHO study finds

Former Nova Scotia health care CEO sentenced for defrauding children’s hospital

Novo Nordisk says generic Ozempic, Wegovy will slow sales in Canada

Raw milk consumption warnings issued after U.S. newborn dies of listeria

What is Nipah virus? What to know about the disease as India faces outbreak

Pizza Pops contaminated with E. coli tied to 7 hospitalizations, data shows

Pizza Pops E. coli recall grows as roughly a dozen products now hit

U.S. finalizes withdrawal from World Health Organization

Editors Picks

Digital car keys are getting more sophisticated

February 8, 2026

Mutuum Finance (MUTM) Crosses $20.4M Funding Milestone After Recent Whale Activity

February 8, 2026

Canada coach looking for cross-country ski medals

February 8, 2026

Coach says Kingsbury races like a Formula One car

February 8, 2026

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Eglinton Crosstown LRT officially opens in Toronto without pomp or ceremony

February 8, 2026

Msheireb Downtown Doha Emerges as GCC Winter Destination, Welcoming 5 Million Visitors

February 8, 2026

5 things to know from Saturday at the Winter Games

February 7, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version